Clozapine: a review of clinical practice guidelines and prescribing trends
Open accessThe DOI matches its Crossref record; 71 of the 72 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
BACKGROUND: Clozapine effectiveness in the treatment of refractory schizophrenia has been sustained by published evidence in the last two decades, despite the introduction of safer options. DISCUSSION: Current clinical practice guidelines have strongly recommended the use of clozapine in treatment-resistant schizophrenia, but prescribing trends do not appear to have followed such recommendations. Clozapine is still underutilized especially in patients at risk of suicide. It seems that physicians are hesitant in prescribing clozapine due to concerns about serious adverse effects. Recent reports have highlighted the need to inform health professionals about the benefits of treating patients with clozapine and have voiced concerns about the underutilization of clozapine especially in patients at risk of suicide. SUMMARY: Guidelines and prescribing patterns reported in various countries worldwide are discussed. Suggestions on how to optimize clozapine utilization have been published but more efforts are needed to properly inform and support prescribers' practices.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“More recently, a meta-analysis of observational and trial data demonstrated that clozapine, when taken consistently, decreased not only suicides, but other causes of mortality as well 305 , although this effect may be partially explained by closer monitoring of patients receiving clozapine treatment.”
From Suicide and suicide risk (2019) · cites this paper as [305]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Comprehensive Textbook of Psychiatry
Freedman, A. M., & Kaplan, H. I. (1967) · The American Journal of the Medical Sciences · doi:10.1097/00000441-196712000-00052 · Cited by 3,799
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561 · cited 8×
“Early studies of SGAs demonstrated superiority over the FGAs, including a lower incidence of EPS, superior efficacy for positive, negative and mood symptoms, improved tolerability, as well as cognitive enhancing effects [5-8].”
BackgroundInfluentialSecond-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
McEvoy, J. P., Lieberman, J. A., Stroup, T. S., Davis, S. M., Meltzer, H. Y., Rosenheck, R. A., Swartz, M. S., Perkins, D. O., Keefe, R. S. E., Davis, C. E., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.600 · Cited by 1,018
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P. R., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp116 · Cited by 907
Leucht, S., Pitschel-Walz, G., Abraham, D., & Kissling, W. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00105-4 · Cited by 796
Research works printed but not linked: 2
- Clozapine Treatment of Hospitalized Patients: A Review of Clinical Practice Guidelines and Safety. Report December 20, 2010 Accessed on August 10, 2012 http://www.cadth.ca/en/search?q=Clozapine +treatment+in+hospitalized
- Netherlands Clozapine Collaboration Group: Guideline for the use of clozapine [English version]. 2009, [Cited 14 July 2010] http://clozapinepluswerkgroep.nl/pdf/SKMBT_C45110040808460.pdf
Cited by
Turecki, G., Brent, D. A., Gunnell, D., O’Connor, R. C., Oquendo, M. A., Pirkis, J., & Stanley, B. H. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0121-0 · Cited by 1,074
Siskind, D., McCartney, L., Goldschlager, R., & Kisely, S. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.115.177261 · Cited by 601
Guidelines for the Pharmacotherapy of Schizophrenia in Adults
Remington, G., Addington, D., Honer, W., Ismail, Z., Raedler, T., & Teehan, M. (2017) · The Canadian Journal of Psychiatry · doi:10.1177/0706743717720448 · Cited by 332
“The present emphasis is on positive symptom severity and response as the key feature for assessment of treatment resistance.26 This focus was also at the core of patient selection criteria and outcome assessment in the landmark study of clozapine in TRS.85 This study required patients to have a moderate level of sever…”
BackgroundInfluentialInternational trends in clozapine use: a study in 17 countries
Bachmann, C. J., Aagaard, L., Bernardo, M., Brandt, L., Cartabia, M., Clavenna, A., Coma Fusté, A., Furu, K., Garuoliené, K., Hoffmann, F., et al. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12742 · Cited by 314
Gillespie, A. L., Samanaite, R., Mill, J., Egerton, A., & MacCabe, J. H. (2017) · BMC Psychiatry · doi:10.1186/s12888-016-1177-y · Cited by 240
Metadata
- Authors
- Warnez, S., & Alessi-Severini, S.
- Affiliations
- University of Manitoba (CA)
- Venue
- BMC Psychiatry
- Published
- 2014-04-07
- Volume
- 14
- Issue
- 1
- Pages
- 102-102
- ISSN
- 1471-244X (ISSN-L)
- PMC
- PMC3999500
- OpenAlex
- W2084250773
- Cited by
- 234
- References
- 71
- Citations by year
- 2026: 3 · 2025: 19 · 2024: 20 · 2023: 18 · 2022: 31 · 2021: 22 · 2020: 21 · 2019: 25 · 2018: 19 · 2017: 19 · 2016: 17 · 2015: 17 · 2014: 2
- FWCI
- 2.52
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- BMC Psychiatry (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Mspace (University of Manitoba) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Keywords
- clozapine, treatment-resistant schizophrenia, prescribing patterns, guideline adherence, suicide risk, adverse effects, antipsychotic prescribing
- MeSH terms
- Clozapine, Humans, Practice Patterns, Physicians', Drug Prescriptions, Schizophrenia, Antipsychotic Agents, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clozapine: a review of clinical practice guidelines and prescribing trends. https://app.cochat.ai/papers/10.1186/1471-244x-14-102
- The paper
- Warnez, S., & Alessi-Severini, S. (2014). Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry. https://doi.org/10.1186/1471-244x-14-102
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.